WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous Leishmaniasis: A phase 2, randomized, double blind, placebo controlled study

PLoS Neglected Tropical Diseases

Volumn 3, Issue 5, 2009, Pages

  Salah, Afif Ben ^a   Buffet, Pierre A ^b   Morizot, Gloria ^b   Massoud, Nathalie Ben ^a   Zâatour, Amor ^a   Ben Alaya, Nissaf ^a   Hamida, Nabil Bel Haj ^a   El Ahmadi, Zaher ^c   Downs, Matthew T ^d   Smith, Philip L ^e   Dellagi, Koussay ^a   Grögl, Max ^f  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b INSTITUT PASTEUR   (France)

^c Direction Régionale de la Santé de Sidi Bouzid ^*  (Tunisia)

^d University of Iowa   (United States)

^e U S ARMY   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; PLACEBO; UNCLASSIFIED DRUG; WR 279396; AMINOGLYCOSIDE; ANTITRYPANOSOMAL AGENT; GENTAMICIN; PAROMOMYCIN; WR279396;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIZATION; FEMALE; HEARING ACUITY; HUMAN; LEISHMANIA MAJOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN LEISHMANIASIS; SKIN ULCER; VERTIGO; ADOLESCENT; AGED; CHILD; DRUG EFFECT; FRANCE; MIDDLE AGED; OINTMENT; PARASITOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; TUNISIA;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FRANCE; GENTAMICINS; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MIDDLE AGED; OINTMENTS; PAROMOMYCIN; PLACEBOS; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TUNISIA; YOUNG ADULT;

EID: 65849094308     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000432     Document Type: Article

References (32)

1. Desjeux P (1992) Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 45: 267-275.
2. Magill AJ (2005) Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am 19: 241-266, x-xi.
3. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C (2004) Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53: 158-166.
4. Buffet P, Caumes E, Gentilini M (1994) [Treatment of localized cutaneous leishmaniasis]. Ann Dermatol Venereol 121: 503-511.
5. Belazzoug S, Neal RA (1986) Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria [letter]. Trans R Soc Trop Med Hyg 80: 670-671.
6. Berman J (2003) Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16: 397-401.
7. Bryceson A (1987) Therapy in man. In: Peters W, K-K R, eds (1987) The leishmaniases. London: Elsevier. pp 847-869.
8. Garnier T, Croft SL (2002) Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 3: 538-544.
9. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A (2003) The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 97: 493-498.
10. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
11. Tulkens PM (1991) Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 10: 100-106.
12. El-On J, Jacobs GP, Witztum E, Greenblatt CL (1984) Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 26: 745-751.
13. el-On J, Halevy S, Grunwald MH, Weinrauch L (1992) Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 27: 227-231.
14. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L (1986) Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 87: 284-288.
15. Arana BA, Mendoza CE, Rizzo NR, Kroeger A (2001) Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65: 466-470.
16. Krause G, Kroeger A (1994) Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 88: 92-94.
17. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R (2004) Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 91: 153-160.
18. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, et al. (1995) A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53: 648-651.
19. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, et al. (1995) A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 53: 162-166.
20. Iraji F, Sadeghinia A (2005) Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Ann Trop Med Parasitol 99: 3-9.
21. Grogl M, Schuster BG, Ellis WY, Berman JD (1999) Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol 85: 354-359.
22. Lecoeur H, Buffet P, Morizot G, Goyard S, Guigon G, et al. (2007) Optimization of Topical Therapy for Leishmania major Localized Cutaneous Leishmaniasis Using a Reliable C57BL/6 Model. PLoS Negl Trop Dis 1: e34. doi:10.1371/journal.pntd.0000034.
23. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, et al. (2002) Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66: 147-151.
24. Lanotte G, Rioux JA, Lepart J, Maazoun R, Pasteur N, et al. (1984) [Numerical cladistics of the phylogeny of the genus Leishmania Ross, 1903 (Kinetoplastida-Trypanosomatidae). Use of enzyme characteristics]. C R Acad Sci III 299: 769-772.
25. Boelaert M, Dujardin JC (1999) Diagnostic PCR with Leishmania donovani specificity. Trop Med Int Health 4: 789.
26. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, et al. (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359: 2188-2194.
27. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (2007) Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 356: 2571-2581.
28. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL (1995) The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35: 577-584.
29. Ozgoztasi O, Baydar I (1997) A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 36: 61-63.
30. Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, et al. (1998) Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994-95. Bull World Health Organ 76: 289-293.
31. Pecoul B, Chirac P, Trouiller P, Pinel J (1999) Access to essential drugs in poor countries: a lost battle? Jama 281: 361-367.
32. Magill AJ (1995) Epidemiology of the leishmaniases. Dermatol Clin 13: 505-523.